ACSS2 inhibition boosts cabozantinib activity in liver cancer models
Preclinical hepatocellular carcinoma models showed that blocking ACSS2 or autophagy enhanced cabozantinib’s antitumor activity by disrupting a TFEB-linked protective response.
Preclinical hepatocellular carcinoma models showed that blocking ACSS2 or autophagy enhanced cabozantinib’s antitumor activity by disrupting a TFEB-linked protective response.
A new study in Genome Medicine reveals that lactate produced by inflamed gut cells fuels an ACSS2-driven histone lactylation feedback ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine